1-13 of 13
David Sidransky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma

Sakibul Huq, Joshua Casaos, Riccardo Serra, Michael Peters, Yuanxuan Xia, Andy S. Ding, Jeff Ehresman, Jayanidhi N. Kedda, Manuel Morales, Noah L. Gorelick, Tianna Zhao, Wataru Ishida, Alexander Perdomo-Pantoja, Arba Cecia, Chenchen Ji, Ian Suk, David Sidransky, Mariana Brait, Henry Brem, Nicolas Skuli, Betty Tyler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (9): 1797–1808.
https://doi.org/10.1158/1535-7163.MCT-19-0572
Published: 02 September 2020
View article titled, Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma
Open the PDF for Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract A016: NOG-EXL mice have superior immune cell engraftment and lineage development in the human immune system (HIS) model, the ImmunoGraft

Bhavna Verma, Maria Mancini, Angela Davies, David Sidransky, Neal Goodwin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A016.
https://doi.org/10.1158/1535-7163.TARG-17-A016
Published: 01 January 2018
View article titled, Abstract A016: NOG-EXL mice have superior immune cell engraftment and lineage development in the human immune system (HIS) model, the ImmunoGraft
Journal Articles

Abstract A018: Patient-derived xenograft (PDX) models of NSCLC reflect clinical drug responses and predict effective treatments for patients

Daniel Ciznadija, Igor Astaturov, Haiying Cheng, Nir Peled, Jennifer Jaskowiak, Angela Davies, David Sidransky
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A018.
https://doi.org/10.1158/1535-7163.TARG-17-A018
Published: 01 January 2018
View article titled, Abstract A018: Patient-derived xenograft (PDX) models of NSCLC reflect clinical drug responses and predict effective treatments for patients
Journal Articles

Abstract A14: Molecular fidelity of patient derived xenograft (PDX) models to original human tumor and to the cancer genome atlas (TCGA)

Ido Ben-Zvi, Ido Sloma, Tin Khor, Daniel Ciznadija, Amanda Katz, David Vasquez, David Sidransky, Keren Paz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A14.
https://doi.org/10.1158/1535-7163.TARG-15-A14
Published: 01 December 2015
View article titled, Abstract A14: Molecular fidelity of patient derived xenograft (PDX) models to original human tumor and to the cancer genome atlas (TCGA)
Journal Articles

Abstract B30: A phase 1 open label, dose-escalation trial evaluating the safety and tolerability of EF-022, macrophage activator, in subjects with advanced solid malignancies

Talia Golan, Raanan Berger, Aliza Ackerstein, Steve Raskin, Alexander M. Lesokhin, David Sidransky, Mark L. Levitt, Hana Gadassi, Uri Yogev, Michal Shahar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B30.
https://doi.org/10.1158/1535-7163.TARG-15-B30
Published: 01 December 2015
View article titled, Abstract B30: A phase 1 open label, dose-escalation trial evaluating the safety and tolerability of EF-022, macrophage activator, in subjects with advanced solid malignancies
Journal Articles

Abstract A8: The ImmunoGraft: A humanized mouse model for translational assessment of immunotherapy in solid tumors

Gilson Baia, David Vasquez, David Cerna, Daniel Ciznadija, David Sidransky, Amanda Katz, Keren Paz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A8.
https://doi.org/10.1158/1535-7163.TARG-15-A8
Published: 01 December 2015
View article titled, Abstract A8: The ImmunoGraft: A humanized mouse model for translational assessment of immunotherapy in solid tumors
Journal Articles

KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells

Diarmuid M. Moran, Patricia B. Trusk, Karen Pry, Keren Paz, David Sidransky, Sarah S. Bacus
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (6): 1611–1624.
https://doi.org/10.1158/1535-7163.MCT-13-0649
Published: 04 June 2014
View article titled, KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
Open the PDF for KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy

Atul Bedi, Xiaofei Chang, Kimberly Noonan, Vui Pham, Rishi Bedi, Elana J. Fertig, Michael Considine, Joseph A. Califano, Ivan Borrello, Christine H. Chung, David Sidransky, Rajani Ravi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2429–2439.
https://doi.org/10.1158/1535-7163.MCT-12-0101-T
Published: 08 November 2012
View article titled, Inhibition of TGF-β Enhances the <em>In Vivo</em> Antitumor Efficacy of EGF Receptor–Targeted Therapy
Open the PDF for Inhibition of TGF-β Enhances the <em>In Vivo</em> Antitumor Efficacy of EGF Receptor–Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido-Laguna, Elizabeth De Oliveira, Belen Rubio-Viqueira, Steven Strawn, Michael J. Wick, James Martell, David Sidransky
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (8): 1311–1316.
https://doi.org/10.1158/1535-7163.MCT-11-0233
Published: 08 August 2011
View article titled, A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Open the PDF for A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR-4: From mice to men: Guiding cancer treatment through Personalized Tumorgraft™ models results in prolonged clinical responses in patients with refractory advanced cancers and discovery of novel predictive biomarkers

Manuel Hidalgo, Steven J. Strawn, Michael Wick, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, David Sidransky, Elizabeth M. Bruckheimer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): PR-4.
https://doi.org/10.1158/1535-7163.TARG-09-PR-4
Published: 10 December 2009
View article titled, Abstract PR-4: From mice to men: Guiding cancer treatment through Personalized Tumorgraft™ models results in prolonged clinical responses in patients with refractory advanced cancers and discovery of novel predictive biomarkers
Journal Articles

Abstract A25: Establishment and characterization of primary human Biomerk Tumorgraft™ Models: Application to oncology drug development

Steven J. Strawn, Michael Wick, Francis Nieves, David Sidransky, Elizabeth M. Bruckheimer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A25.
https://doi.org/10.1158/1535-7163.TARG-09-A25
Published: 10 December 2009
View article titled, Abstract A25: Establishment and characterization of primary human Biomerk Tumorgraft™ Models: Application to oncology drug development
Journal Articles

The oncogenic property of Aquaporin 5 (AQP5): Human AQP5 plays a role in proliferation of chronic myelogenous leukemia (CML) cells.

Young Kwang Chae, Jong Chul Park, Sung Koo Kang, Juna Lee, David Sidransky, Chulso Moon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C74.
Published: 01 November 2007
View article titled, The oncogenic property of Aquaporin 5 (AQP5): Human AQP5 plays a role in proliferation of chronic myelogenous leukemia (CML) cells.
Journal Articles

Aquaporin 5 (AQP5) is a novel signaling molecule triggering Ras/ERK/retinoblastoma (Rb) signaling pathway in colon cancer cell lines

Sung Koo Kang, Janghee Woo, Young Kwang Chae, Myoung Sook Kim, Jin Hyen Baek, Jong Chul Park, Juna Lee, Minjoo Park, Barry Trink, Edward Ratovitski, Taekyul Lee, Beomsoo Park, Jean Soria, Joseph Califano, Se Jin Jang, David Sidransky, Chulso Moon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B115.
Published: 01 November 2007
View article titled, Aquaporin 5 (AQP5) is a novel signaling molecule triggering Ras/ERK/retinoblastoma (Rb) signaling pathway in colon cancer cell lines